Beni-Suef University Journal of Basic and Applied Sciences最新文献

{"title":"Bibliometric analysis on the pharmacological/therapeutic effects of earthworms (Dilong)","authors":"Xinyue Luo,&nbsp;Mengjie Du,&nbsp;Wei Huang,&nbsp;Ping Wu,&nbsp;Shuyu Zhang,&nbsp;Wenbo Liu","doi":"10.1186/s43088-026-00835-x","DOIUrl":"10.1186/s43088-026-00835-x","url":null,"abstract":"<div><h3>Background</h3><p>In Traditional Chinese Medicine (TCM), earthworm (Dilong) has been used for over two millennia in clinical practice. However, most existing studies focus on individual bioactive components or specific diseases, and the broader landscape of global research on their pharmacological effects has remained largely unexplored.</p><h3>Methods</h3><p>This study conducted a bibliometric analysis of the pharmacological and therapeutic effects of earthworms (Dilong), aiming to identify current research hotspots, emerging trends, and collaborative networks (authors, institutions, countries) in this field. Data were retrieved from the Web of Science (WoS) Core Collection and analyzed using Bibliometrix and CiteSpace.</p><h3>Results</h3><p>A total of 313 publications were identified for the period 1989–2024. The results showed a steady increase in the number of publications on the pharmacological and therapeutic effects of earthworms. More than 60% of the publications originated from Asia, with China the leading contributor (34.2%), followed by the United States. The most productive author was Prof. Edwin Cooper (University of California, Los Angeles; <i>n</i> = 16 publications, 566 citations). Keyword analysis revealed three major research clusters: characterization of bioactive proteins (notably lumbrokinase and antimicrobial peptides), mechanistic investigation of anti-inflammatory and antitumor activities, and thrombolytic and cardiovascular applications. Current research hotspots center on the purification and functional characterization of earthworm-derived proteins, with high-impact studies increasingly incorporating advanced methodologies such as cryo-electron microscopy and nanoparticle-based delivery systems. Evidence for pharmacological effects derives predominantly from in vitro assays and animal models; robust clinical data remain limited.</p><h3>Conclusion</h3><p>This bibliometric analysis provides a systematic overview of the evolving research landscape in earthworm-based pharmacology, mapping key contributors, thematic clusters, and emerging trends from 1989 to 2024. The findings suggest that earthworm-derived compounds may exert diverse therapeutic effects, including thrombolysis, antimicrobial, anti-inflammatory, and antitumor activities, though most evidence currently derives from preclinical studies. Future work should prioritize multicenter clinical trials, standardized quality control, comprehensive multi-omics characterization, exploration of nanodelivery systems, and One Health–oriented applications to accelerate translation from traditional use to evidence-based therapeutics.</p><h3>Clinical trial number</h3><p>Not applicable.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00835-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective mechanisms of the brown alga Cystoseira myrica supplementation against testicular alterations in streptozotocin-induced diabetic rats","authors":"Doaa A. Ali","doi":"10.1186/s43088-026-00807-1","DOIUrl":"10.1186/s43088-026-00807-1","url":null,"abstract":"<div><h3>Background</h3><p>Diabetes (DM) is a significant public health issue associated with the increased risk of male infertility. Brown seaweeds are excellent sources of bioactive compounds with multiple biological activities. This study investigates the protective mechanisms of brown alga <i>Cystoseira myrica</i> against the testicular lesion of diabetic animals.</p><h3>Methods</h3><p>DM was induced in male rats using a single intraperitoneal injection of streptozotocin (STZ). Animals were fed a diet supplemented with 2% <i>Cystosira</i> for 60 days, concurrently with STZ administration. Blood and testis tissues were sampled for biochemical, histopathological and immunohistochemical investigations.</p><h3>Results</h3><p>STZ treated animals showed significant decrease in serum testosterone, superoxide dismutase (SOD) and catalase (CAT) activities along with a significant elevation in malondialdehyde (MDA) level, indicating oxidative stress. However, <i>Cystoseira</i> supplementation to STZ diabetic animals significantly increased the above mentioned data and significantly reduced MDA level with respect to STZ treated group. Histological and ultrastructural evaluations revealed that <i>Cystoseira</i> ameliorated STZ-induced degenerative changes in seminiferous tubules and preserved spermatogenic cell integrity. Immunohistochemically, <i>Cystoseira</i> supplementation to STZ treated animals markedly upregulated PCNA and Bcl-2 expression while down regulating Bax, reflecting enhanced cell proliferation and reduced apoptosis, further supporting its potent antiapoptotic and cytoprotective efficacy. Consistently, AO/EB dual staining confirmed a decrease in apoptotic spermatogenic cells.</p><h3>Conclusion</h3><p>This study provides the first evidence that <i>Cystoseira myrica</i> protects against diabetes-induced testicular damage by enhancing antioxidant capacity, restoring hormonal balance, and regulating apoptotic signaling. These findings suggest that <i>Cystoseira myrica</i> represents a promising bioactive nutritional supplement for preserving spermatogenic function and mitigating male reproductive complications associated with diabetes.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00807-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy","authors":"Lhoucine Naanaai,&nbsp;Abdellah El Aissouq,&nbsp;Yassine El Allouche,&nbsp;Youssra Ech-Chahdi,&nbsp;Hicham Zaitan,&nbsp;Fouad Khalil","doi":"10.1186/s43088-026-00816-0","DOIUrl":"10.1186/s43088-026-00816-0","url":null,"abstract":"<div><p>The MGC803 cell line is a human gastric cancer model frequently used in cancer research. In this context, a combined in silico approach including 3D-QSAR modeling, ADMET analysis, network pharmacology, docking, molecular dynamics and ligand transport evaluations, was applied to design new antiproliferative molecules. A robust 3D-QSAR model with high predictive capacity (<i>R²</i> and <i>Q²</i>) was developed and used to design new compounds (PR1–PR4). After an ADMET screening, the putative biological targets of the non-toxic compounds were predicted using PharmMapper. A network pharmacology analysis identified several hub genes, of which HSP90AA1 had the highest degree value. Given its central role in stabilizing multiple oncogenic proteins involved in gastric cancer progression, as well as its suitability for structure-based studies, HSP90AA1 was selected for molecular docking and molecular dynamics simulations. In addition, molecular docking was performed on HSP90AA1 protein (1YET) in complex with the designed molecules (PR1-PR4), and their predicted binding behaviors were compared to both the most active molecule (M34) and the reference drug, geldanamycin. These results demonstrate a high predicted binding affinity and remarkable interaction profiles within the active site of the HSP90AA1. To further evaluate the dynamic stability of these complexes, we performed molecular dynamics simulations over a 100 ns period, thus confirming stable attachment modes and durable contact networks. The MM-PBSA approach demonstrated favorable binding free energies between the chosen PR4 ligand and the 1YET protein (-26.47 ± 2.89 kcal/mol). Finally, the ligand transport study showed that the PR4 ligand easily crosses tunnels 1 and 2 with optimal theoretical transport dynamics compared to the reference drug, geldanamycin (GA). This comprehensive computational method underlines the diverse potential of the examined molecules, identifying the most promising candidates for subsequent experimental validation against gastric cancer.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00816-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic relationship between plant extracts, essential oils, phytocompounds and antibiotics in controlling drug resistant bacterial species","authors":"Rajni Dhalaria,&nbsp;Khomaizon Abdul Kadir Pahirul Zaman,&nbsp;Mehak Thakur,&nbsp;Sumayya Sana Shaikh,&nbsp;Renata Knop,&nbsp;Ayaz Mukarram Shaikh,&nbsp;Asgar Ali","doi":"10.1186/s43088-026-00815-1","DOIUrl":"10.1186/s43088-026-00815-1","url":null,"abstract":"<div><h3>Background</h3><p>Antimicrobial resistance (AMR) has emerged as a global threat to global public health, requiring innovative strategies to address antibiotic-resistant bacterial pathogens. The synergy between plant extracts, essential oils, phytocompounds, and antibiotics promises to be a viable solution to this grave issue.</p><h3>Main body</h3><p>In addition to the synergistic effects of plant extracts, essential oils, and phytocompounds, the current review described the main groups of phytochemicals that function as anti-bacterial agents. The mechanical and toxicological issues are also highlighted in the current review.</p><h3>Conclusion</h3><p>The most popular techniques examined in this review are checkerboard and time-kill tests. The synergistic actions of plant extracts, phytocompounds, and essential oils effectively reduced the drug’s minimal inhibitory concentration against both standard and clinical bacterial isolates. Each of the three complementary strategies-plant extracts, phytocompounds, and essential oils-was equally significant.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00815-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted nanocarriers in gastric cancer: a critical review of HER2, CLDN18.2 and EGFR-directed translational evidence","authors":"Guoying Jiang,&nbsp;Guobing Wang,&nbsp;Jun Tao,&nbsp;Wenqi Feng","doi":"10.1186/s43088-026-00822-2","DOIUrl":"10.1186/s43088-026-00822-2","url":null,"abstract":"<div><h3>Purpose</h3><p>Targeted nanocarriers are increasingly proposed to overcome therapeutic resistance and peritoneal recurrence in gastric cancer (GC), yet clinical translation remains limited and, in our reading, systematically over-promised. This review addresses three conflated questions: whether HER2, CLDN18.2, and EGFR function not only as disease targets but as reliable nanocarrier gateways; which delivery barriers are realistically engineerable rather than merely describable; and why preclinical efficacy has rarely advanced to clinical benefit despite a decade of activity.</p><h3>Methods</h3><p>A structured narrative search of PubMed, Web of Science, and Google Scholar identified English-language literature (January 2014–April 2026) on GC nanocarriers, platforms, molecular targeting, trial registries (ClinicalTrials.gov) and translational nanomedicine. From 1,247 records, 186 GC-relevant studies were retained and classified across evidentiary tiers, and re-read for what they omitted—untargeted controls, quantitative biodistribution, orthotopic or peritoneal-metastasis modelling, and molecular-subtype stratification.</p><h3>Results</h3><p>HER2-directed nanocarriers are constrained by intratumoral heterogeneity and dynamic target loss, with most positive data from uniformly HER2-high cell lines. CLDN18.2 offers stronger specificity but faces assay-dependent prevalence, tight-junction sequestration limiting ligand access, and accelerating antibody-drug conjugate (ADC) competition. EGFR remains exploratory, as antibody failure (EXPAND, REAL3) is unreconciled with nanocarrier reuse and normal-tissue expression imposes a toxicity ceiling. Across platforms, nanoformulation reproducibly improves tolerability but rarely enhances intratumoral delivery, often reflecting solubilizer removal rather than a true “nano-effect”. Progress is further limited by overreliance on subcutaneous xenografts and near-absent integration of subtype, route, and manufacturability.</p><h3>Conclusion</h3><p>GC nanomedicine should shift from platform enthusiasm to disease-specific translational discipline. Intraperitoneal nanocarriers for peritoneal metastasis carry the highest near-term potential, whereas heterogeneity-ignoring HER2 and ADC-ignoring CLDN18.2 monotherapy programmes, and the emphasis on multi-stimuli-responsive and exosome-based delivery, risk being overstated. Future studies require route-specific design, subtype-guided selection, targeted-versus-untargeted controls, quantitative biodistribution, orthotopic/peritoneal validation, and an agreed minimum translational dataset.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00822-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of bioinformatics approaches to understand drug resistance and identifying novel inhibitors against multidrug-resistant Mycobacterium tuberculosis","authors":"Elizabeth Annie George,&nbsp;Mahima Senthilkumar,&nbsp;Kavitha Thirupugazh,&nbsp;Shivani Rajesh,&nbsp;Mahasaraswathi Chockalingam,&nbsp;Sudha Ramaiah,&nbsp;Anand Anbarasu","doi":"10.1186/s43088-026-00825-z","DOIUrl":"10.1186/s43088-026-00825-z","url":null,"abstract":"<div><h3>Background</h3><p>The rapid emergence of multidrug-resistant <i>Mycobacterium tuberculosis</i> (MDR-TB) has significantly reduced the effectiveness of conventional therapeutic regimens necessitating the discovery of novel drug targets and inhibitors.</p><h3>Main Body</h3><p>Recent bioinformatics-driven approaches for identifying putative inhibitors targeting essential mycobacterial proteins are comprehensively reviewed. Unlike previous reviews that tend to focus either on drug resistance mechanisms or drug discovery using computational approaches separately, this review integrates both aspects by linking genetic mutations associated with drug resistance and advanced computational approaches for anti-TB drug discovery. Integrative computational strategies including subtractive genomics, molecular docking, molecular dynamics simulations and machine learning-based prioritisation are emphasised. These approaches enable the identification of pathogen specific targets with minimal homology with the host proteins. This review further highlights the importance of natural products, peptides and drug repurposing strategies in targeting MDR-TB. Computational pipelines have shown the potential to greatly speed up early-stage drug discovery while lowering related costs and time, despite the challenges. The benefits of combining multi-omics data with artificial intelligence to create strain-specific treatment approaches are further demonstrated by case-based insights. Furthermore, this review highlights the current challenges in translating computational predictions into experimental and clinical validation while providing future directions including AI/ML based drug discovery, network pharmacology, host-directed therapies, and personalized medicine.</p><h3>Conclusion</h3><p>Overall, this review underscores the critical role of bioinformatics in addressing the global burden of MDR-TB and highlights its transformative role in guiding next-generation anti-TB drug development.</p><h3>Clinical trial number</h3><p>Not applicable.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00825-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidiabetic action of Cleome droserifolia through direct interaction with pancreatic islet beta cell FABP3","authors":"Hekmat El-gammal,&nbsp;Noriya Ebeed,&nbsp;Kadry El-Bakry,&nbsp;Ayman Hyder","doi":"10.1186/s43088-026-00830-2","DOIUrl":"10.1186/s43088-026-00830-2","url":null,"abstract":"<div><h3>Background</h3><p><i>Cleome droserifolia</i> (Forssk.) Delile (Cleomaceae) is traditionally used in Egypt and other countries to manage a variety of diseases, including diabetes. Its antihyperglycemic effect is unconvincingly linked to its general antioxidant and anti-inflammatory effect. More specific antidiabetic mechanisms remain unexplored. In this context, fatty acid binding protein 3 (FABP3) is expressed by pancreatic islet beta cells; suppression of this protein has been shown to shield beta cells from lipotoxicity. This work investigates the possible relation of <i>C. droserifolia</i> bioactive components to FABP3 and its direct effects on pancreatic islets of a type 2 diabetes animal model.</p><h3>Methods</h3><p>Here, fractionated constituents of <i>C. droserifolia</i> were evaluated for their possible binding to FABP3 by in silico molecular docking. Four-week-old rats were fed a high-fat/high-fructose diet (HFHFD) mixed with aqueous or ethanolic extract of <i>C. droserifolia</i> for 16 weeks to investigate the effect on the glycemic and lipidemic states during the development of the diabetic model.</p><h3>Results</h3><p><i>Cleome droserifolia</i> inhibited the progression of HFHFD-induced obesity, hyperglycemia, hyperinsulinemia, impaired glucose tolerance test, insulin resistance, and dyslipidemia. Molecular docking results showed that many compounds of <i>C. droserifolia</i>, such as cleomaldeic acid, cleomeolide, luteolin, kaempferol, amblyone, and brachycarpone, can strongly bind onto FABP3 and occupy its binding pocket. In beta cells of rats, which concurrently fed HFHFD and <i>C. droserifolia</i>, fewer lipid droplets, immune cell infiltration, inflammatory, and apoptotic responses were observed.</p><h3>Conclusion</h3><p>Components of <i>C. droserifolia</i> competitively inhibit the binding of FABP3 with native fatty ligands, limiting lipid-induced deterioration of beta cells. The antidiabetic action of <i>C. droserifolia</i> can be attributed to this direct beneficial effect on pancreatic islet beta cells.</p><h3>Clinical trial number</h3><p>Not applicable.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00830-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148837576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory and inflammation-associated pain-modulating effects of azilsartan in preclinical models","authors":"Shubham Atal,&nbsp;Santenna Chenchula,&nbsp;P. Ponmani,&nbsp;Jai Kumar Chaurasia,&nbsp;Malaya Nanda,&nbsp;K. Chandrahasan,&nbsp;Arti Shrivastava,&nbsp;S. Balakrishnan","doi":"10.1186/s43088-026-00823-1","DOIUrl":"10.1186/s43088-026-00823-1","url":null,"abstract":"<div><h3>Introduction</h3><p>Azilsartan, an angiotensin receptor blocker, has been widely used in the treatment of hypertension. Its unique structure is hypothesised to confer multiple pleiotropic effects, including anti-inflammatory and anti-apoptotic properties, with potential antioxidant effects being exploratory. The present study was conducted to evaluate the anti-inflammatory, antinociceptive, and antioxidative properties of azilsartan in thermally and chemically induced nociceptive rodent models.</p><h3>Materials and methods</h3><p>Wistar albino rats (200–250 g) and Swiss albino mice (25–30 g) of either sex were procured from the Central Animal Facility, AIIMS Bhopal. Two doses of azilsartan (1 mg/kg and 4 mg/kg) were investigated after approval from the institutional animal ethics committee. Anti-inflammatory and anti-nociceptive properties were evaluated using chemically induced inflammatory models, including carrageenan, Freund’s complete adjuvant (FCA)-induced arthritis, thermally induced nociceptive models and Aspirin-induced gastric ulcer.</p><h3>Results</h3><p>Azilsartan produced significant anti-inflammatory effects in chemically induced models. In the carrageenan-induced paw edema model, at 6 h, paw volume was reduced to 1.59 ± 0.02 ml with azilsartan 4 mg/kg vs. 1.86 ± 0.01 ml in controls (32% inhibition, <i>p</i> &lt; 0.01). In the FCA-induced arthritis model, by day 14, joint size was reduced by 27% with azilsartan 4 mg/kg (<i>p</i> &lt; 0.05 vs. control). Histopathological and immunohistochemical analyses demonstrated reduced inflammatory infiltration and decreased TNF-α expression in azilsartan-treated groups. Azilsartan also showed dose-dependent protection against aspirin-induced gastric ulceration, with 36% and 45% inhibition at doses of 1 and 4 mg/kg, respectively (<i>p</i> &lt; 0.001). Mean MDA levels were 350 pg/mL in controls vs. 115 pg/mL with azilsartan 4 mg/kg (<i>p</i> = 0.12). No significant analgesic effect was observed in thermally induced nociceptive models (hot plate and tail flick tests).</p><h3>Conclusion</h3><p>Azilsartan exhibits significant anti-inflammatory and inflammation-associated pain–modulating effects in preclinical models, but does not demonstrate significant analgesic activity in acute thermal nociception.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div><h3>Clinical trial number</h3><p>Not applicable.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00823-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148837598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic CRISPR/Cas9 delivery approaches: strengths, limitations, and a roadmap for clinical translation","authors":"Maryam Rezaee,&nbsp;Farideh Izadi,&nbsp;Saeed Nobaharian,&nbsp;Leila Hassani,&nbsp;Esmaeil Rezaei,&nbsp;Sara Sadeghi Amini,&nbsp;Ali Akbar Pourfathollah,&nbsp;Ali Kowsari,&nbsp;Sirous Naeimi,&nbsp;Khalil Khashei Varnamkhasti,&nbsp;Leila Rouhi","doi":"10.1186/s43088-026-00824-0","DOIUrl":"10.1186/s43088-026-00824-0","url":null,"abstract":"<div><h3>Background</h3><p>CRISPR/Cas9 has revolutionized genetic engineering since its repurposing as a programmable nuclease in 2012, yet its clinical translation remains fundamentally constrained by delivery barriers rather than editing efficiency. The system operates through acquisition, biogenesis, and interference mechanisms, but therapeutic application necessitates overcoming delivery challenges that are highly context-dependent.</p><h3>Main body</h3><p>This review moves beyond a descriptive summary of 67 studies to provide a critical, barrier-focused analysis of delivery strategies. Our re-analysis of the tabulated data identifies quantitative trends across viral, non-viral, and physical platforms, evaluates trade-offs between efficiency and safety, and proposes a decision framework for vehicle selection based on target tissue and cargo type. A major focus of this review is the inclusion of recent hybrid systems (VLPs, SORT-LNPs) and the recognition that chemical modification of guide RNAs is a critical parameter for therapeutic success. A key forward-looking insight is that hybrid systems and stimuli-responsive nanoparticles are poised to dominate the next 5 years of clinical development, particularly for liver, CNS, and hematopoietic targets.</p><h3>Conclusion</h3><p>Successful clinical translation of CRISPR/Cas9 will depend on context-specific delivery strategies that balance editing efficiency, safety, and clinical scalability.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00824-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148783208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postharvest management of fungal pathogens of selected fruits: role of plant extracts, essential oils, edible films/coatings, and green nanoparticles","authors":"Harsh Kumar,&nbsp;Kamil Kuca,&nbsp;Nidhi Sethi,&nbsp;Mehak Thakur,&nbsp;Mohd Tariq,&nbsp;Hasnita Binti Che Harun,&nbsp;Lukas Peter,&nbsp;Marek Zdaniewicz,&nbsp;Ayaz Mukarram Shaikh,&nbsp;Béla Kovács,&nbsp;Endre Harsányi","doi":"10.1186/s43088-026-00821-3","DOIUrl":"10.1186/s43088-026-00821-3","url":null,"abstract":"<div><h3>Background</h3><p>Fruits such as mango (<i>Mangifera indica</i>), apple (<i>Malus × domestica</i> ), tomato (<i>Solanum lycopersicum</i>), and strawberry (<i>Fragaria × ananassa</i>), are consumed worldwide and fall under a highly economical category of crops. In contrast, the postharvest management against fungal infections particularly remains a challenge for maintaining the quality standards of these fruits. For decades, farmers have been dependent upon synthetic fungicides, thus having a serious impact on human health as well as the overall ecosystem. In order to avoid such situations, diverse research laboratories around the world have discovered safe alternatives to these chemical fungicides.</p><h3>Main body</h3><p>The current review aims to summarize as well as analyze the substitute postharvest treatments, including plant extracts, edible films/coatings, green metallic nanoparticles, and plant-based essential oils for controlling fungal infections. The review also highlights the challenges related to each methodology.</p><h3>Conclusion</h3><p>Natural fungicides effectively kill or inhibit postharvest fungi in addition to maintaining the overall fruit quality that is of utmost importance for retailers, farmers, and ultimate consumers.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00821-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}